Clinical trialUNITERAREApr 3
Researchers are testing a new medicine called glycerol tributyrate to see if it can help people with two rare mitochondrial diseases: MELAS (a condition that causes brain inflammation, acid buildup in the blood, and stroke-like episodes) and LHON-Plus (a condition that damages the optic nerve and causes vision loss). This is an early-stage study that will enroll patients starting in April 2026.
WHY IT MATTERSThis is the first clinical trial testing glycerol tributyrate specifically in MELAS and LHON-Plus patients, offering a potential new treatment option for these currently untreatable mitochondrial disorders.
Clinical trialCLINICALTRIALSApr 2
Researchers in France are studying a new tool called MEKANOS that measures how strong bones are and predicts fracture risk in people with fibrous dysplasia, a rare bone disease. This clinical trial involves 20 patients and aims to solve a major problem doctors face: they currently have no good way to know which patients are at highest risk of bone breaks. The study could help doctors make better treatment decisions for this condition.
WHY IT MATTERSThis trial addresses a critical gap in fibrous dysplasia care—doctors currently lack reliable tools to predict which patients will experience fractures, making this the first systematic assessment of fracture risk in this population.
ResearchBIORXIVApr 2
Researchers discovered that mutations in a gene called THAP12 cause a severe type of childhood epilepsy called developmental and epileptic encephalopathy. Two siblings with this condition had two broken copies of the THAP12 gene (one from each parent), which stopped the gene from making enough of its protein. This finding helps explain why some children develop severe seizures early in life and could lead to better diagnosis and treatment options.
WHY IT MATTERSFamilies with children diagnosed with infantile spasms or Lennox-Gastaut syndrome now have a new genetic cause to test for, which could explain their child's condition and guide future treatment decisions.
ResearchBIORXIVApr 2
Researchers developed a new artificial intelligence system called GEN-KnowRD to help doctors recognize rare diseases faster and more accurately. Currently, patients with rare diseases wait years for a correct diagnosis because doctors don't have good tools to identify these uncommon conditions. This new AI system is designed to work better than previous attempts by using a smarter approach that doesn't require as much expert knowledge to keep updated.
WHY IT MATTERSFaster rare disease diagnosis could reduce the average diagnostic odyssey from years to months, allowing patients to access treatment and clinical trials earlier when interventions are most effective.
Clinical trialCLINICALTRIALSApr 1
Researchers are testing a new technology called SmartMatch that helps doctors find the best cancer medicines for patients with rare brain and spinal cord tumors. The technology works by taking a small piece of tumor removed during surgery and testing it against different drugs to see which ones work best. The study wants to see if SmartMatch can complete this analysis and give doctors a report within 3 weeks of surgery. This trial is looking for 80 patients with various types of brain tumors.
WHY IT MATTERSThis trial offers patients with recurrent or advanced brain tumors access to personalized drug testing that could identify the most effective treatment for their specific tumor type within weeks of surgery.
Clinical trialCLINICALTRIALSApr 1
Researchers are testing a combination of two cancer drugs called dabrafenib and trametinib in patients with rare tumors that have a specific genetic change called BRAF V600E. This is a phase IV study, which means the drugs have already been approved and doctors are gathering more information about how well they work. The study will include children (age 1 and up) and adults, and is currently looking for 40 patients to participate.
WHY IT MATTERSIf you have a rare solid tumor with a BRAF V600E mutation and your doctor has already recommended dabrafenib plus trametinib treatment, this trial offers an opportunity to participate in research that could help future patients while receiving the same treatment your doctor planned for you anyway.
Clinical trialCLINICALTRIALSApr 1
Researchers are looking for 88 people with Fragile X Syndrome or Creatine Transporter Deficiency to test a new imaging technology that can see how the brain works. Both of these are genetic conditions that affect how the brain develops and cause intellectual disability. This study might help doctors better understand and diagnose these conditions in the future.
WHY IT MATTERSThis trial is recruiting patients with two of the most common X-linked intellectual disability disorders and may provide a new diagnostic tool that could improve how these conditions are identified and monitored.
Clinical trialCLINICALTRIALSApr 1
Researchers are looking for 3,100 people to join a study about why patients don't take their medications as prescribed. The study will test a new approach to help people stick to their treatment plans, which could improve their health and reduce unnecessary hospital visits. About half of all patients don't take their medicines the right way, and this problem gets worse when treatment also requires lifestyle changes.
WHY IT MATTERSThis trial directly addresses medication non-adherence across multiple rare disease categories, meaning patients with rare conditions could benefit from proven strategies to better manage their treatments and health outcomes.
ResearchCONGRESSApr 1
Researchers studied how life circumstances like poverty, access to healthcare, and education affect children with developmental delays and intellectual disabilities. They also looked at how long it takes families to get a diagnosis and whether genetic testing helps. The study suggests that where you live and your resources matter a lot in getting answers for why a child has developmental challenges.
WHY IT MATTERSThis research highlights that children from disadvantaged backgrounds face longer diagnostic journeys for developmental delays—meaning families may wait years longer to understand their child's condition and access support services.
ResearchPUBMEDApr 1
Scientists are developing a new technology called Digital Twins—computer models that act like virtual copies of individual patients. These virtual copies could help doctors diagnose rare childhood diseases faster and find better treatments by testing ideas on the computer before trying them on real patients. This is especially helpful for rare diseases because there aren't many patients to study, and it's hard to do traditional research on children.
WHY IT MATTERSDigital twins could speed up diagnosis and enable personalized treatment plans for children with rare diseases, potentially reducing the years of diagnostic delay that currently affects most pediatric rare disease patients.
ResearchPUBMEDApr 1
Researchers studied whether the amount of cancer in a patient's body before treatment affects how well two immunotherapy drugs work together. They looked at 722 patients with rare cancers who received nivolumab and ipilimumab (two drugs that help the immune system fight cancer). The study wanted to understand if patients with smaller tumors do better than those with larger tumors when treated with these combination drugs.
WHY IT MATTERSIf baseline tumor size predicts treatment response in rare cancers, doctors could better counsel patients on expected outcomes and identify which patients might benefit most from this dual immunotherapy approach before starting treatment.
ResearchPUBMEDApr 1
Researchers in Turkey tested a new questionnaire called the Parental Needs Scale for Rare Diseases to measure what parents of children with rare diseases need most. The study included 264 parents and used statistical tests to make sure the questionnaire works well and gives consistent results. This tool can help doctors and support programs better understand and meet the needs of families dealing with rare diseases.
WHY IT MATTERSThis validated assessment tool enables healthcare systems to systematically identify and address the specific economic, emotional, and physical support needs of parents caring for children with rare diseases, potentially improving family quality of life and care outcomes.
ResearchPUBMEDApr 1
Researchers in Italy tested a new way to diagnose rare genetic diseases in children using whole genome sequencing—a test that reads all of a person's genetic code. Between 2018 and 2022, they studied 64 children with complex neurological problems that doctors couldn't figure out. This study shows whether this genetic test could help find answers faster for kids with mysterious rare diseases.
WHY IT MATTERSIf your child has unexplained neurological symptoms and multiple doctors haven't found a diagnosis, this research demonstrates that whole genome sequencing through healthcare systems may finally provide answers—potentially ending years of diagnostic uncertainty.
PolicyPUBMEDApr 1
A European network for rare connective tissue diseases has created a new model where patients are treated as equal partners in research and care decisions. Instead of doctors alone deciding what to study and how to treat patients, this network includes patients in every step—from identifying problems to writing research papers together. This approach helps address long diagnostic delays and gaps in care that patients with these rare diseases often face.
WHY IT MATTERSPatients with rare connective tissue diseases can now directly influence research priorities and treatment approaches through structured partnership roles, rather than having decisions made without their input.
ResearchPUBMEDApr 1
Scientists are developing a new way to study rare bone diseases using lab-grown bone tissue called organoids. Instead of only using animal tests or simple cell cultures, researchers can now grow tiny bone structures that act like real bones. This helps them understand why these diseases happen and test new treatments more accurately before trying them in patients.
WHY IT MATTERSFor patients with rare skeletal disorders, bone organoids could speed up the discovery of treatments by allowing researchers to test drugs on disease-specific bone tissue grown from patient cells, potentially leading to personalized medicine approaches.
PolicyPUBMEDApr 1
Researchers compared how quickly rare disease drugs become available in China versus the United States between 2001 and 2024. The study looked at a problem called 'drug loss' — when medicines are approved in the US but never reach Chinese patients — and 'drug lag' — when there's a long delay before Chinese approval. The findings help the Chinese government understand what's blocking patients from getting treatments that already exist elsewhere in the world.
WHY IT MATTERSIf you have a rare disease in China, this research directly impacts whether you can access treatments that may already be approved and available in the United States, potentially identifying barriers your doctor or patient advocacy groups can help address.
ResearchPUBMEDApr 1
Researchers reviewed 78 studies about early satiety (feeling full quickly after eating small amounts) in cancer patients. They found this symptom is common but often overlooked, and doctors don't have consistent ways to measure or describe it. The review shows there are big gaps in how we understand and treat this problem for cancer patients.
WHY IT MATTERSEarly satiety causes cancer patients to eat less and lose weight, which can weaken their ability to fight cancer and recover from treatment—but doctors rarely screen for or address this specific symptom.
ResearchPUBMEDApr 1
Researchers in Brazil studied dental care for children and teens with rare diseases at five specialized centers. They found that over 1,000 young patients with 244 different rare diseases received dental treatment, with blood-related diseases being the most common. On average, kids didn't see a dentist for the first time until age 8, and many had to travel far from home to get specialized dental care.
WHY IT MATTERSThis study shows that children with rare diseases often wait years before receiving dental care and face significant travel barriers—highlighting a critical gap in specialized dental services that families should advocate for in their own communities.
ResearchPUBMEDApr 1
Researchers tested whether people could get genetic testing (genome sequencing) without always needing to see a genetics specialist first. They studied 313 people of all ages who had unexplained symptoms and could refer themselves or be referred by any doctor. The study found that people who referred themselves were just as likely to get a diagnosis as those referred by specialists. This suggests a new way to make genetic testing available to more people while still having genetics experts review the results.
WHY IT MATTERSIf this hybrid model works, patients with rare diseases could access genome sequencing faster and more easily without waiting for a genetics specialist appointment, potentially shortening the diagnostic odyssey that many rare disease patients experience.
Clinical trialCLINICALTRIALSMar 31
Researchers are building a large international database to collect information and tissue samples from children, teens, and young adults with rare brain tumors. By gathering this data from 5,800 patients, scientists hope to better understand these uncommon cancers and develop better treatments. The study is currently looking for patients to participate.
WHY IT MATTERSThis registry directly addresses rare brain tumors like astroblastoma and BCOR ITD sarcoma that have limited research data—participating patients contribute to the only large-scale international effort to understand these specific tumor types.